See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Aptose Biosciences, Inc. (APTO) - free report >>
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aptose Biosciences, Inc. (APTO) - free report >>
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
Image: Bigstock
Autolus Therapeutics (AUTL) Surges: Stock Moves 9.2% Higher
Autolus Therapeutics plc (AUTL - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This reverses the recent trend for the company—as the stock is now down 2.9% in the past one-month time frame.
The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Autolus Therapeutics has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Autolus Therapeutics PLC Price
Autolus Therapeutics PLC price | Autolus Therapeutics PLC Quote
Investors interested in the Medical – Biomedical and Genetics industry may consider Aptose Biosciences, Inc. (APTO - Free Report) which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>